ID   Mel270
AC   CVCL_C302
SY   MEL270; Mel-270; Mel 270
DR   cancercelllines; CVCL_C302
DR   Cell_Model_Passport; SIDM01845
DR   Cosmic; 848330
DR   Cosmic; 899898
DR   Cosmic; 916144
DR   Cosmic; 986621
DR   Cosmic; 1628396
DR   Cosmic; 1669124
DR   Cosmic; 2036707
DR   DepMap; ACH-002014
DR   IARC_TP53; 23397
DR   ICLC; HTL13002
DR   Wikidata; Q54905163
RX   PubMed=9247253;
RX   PubMed=16772116;
RX   PubMed=22236444;
RX   PubMed=22383533;
RX   PubMed=23849826;
RX   PubMed=28018010;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   From: Ksander B.; Schepens Eye Research Institute; Boston; USA.
CC   Sequence variation: Mutation; HGNC; 4390; GNAQ; Simple; p.Gln209Pro (c.626A>C); ClinVar=VCV000375957; Zygosity=Homozygous (PubMed=22236444; PubMed=22383533).
CC   Misspelling: Mel207; Cosmic=848330.
CC   Derived from site: In situ; Eye, uvea; UBERON=UBERON_0001768.
ST   Source(s): DepMap=ACH-002014; ICLC=HTL13002; PubMed=22236444
ST   Amelogenin: X (ICLC=HTL13002)
ST   Amelogenin: X,Y (PubMed=22236444; DepMap=ACH-002014)
ST   CSF1PO: 11
ST   D13S317: 12
ST   D16S539: 12
ST   D18S51: 19
ST   D21S11: 28,29
ST   D3S1358: 16
ST   D5S818: 12
ST   D7S820: 8,9
ST   D8S1179: 8,13
ST   FGA: 24,26 (DepMap=ACH-002014)
ST   FGA: 26 (PubMed=22236444)
ST   Penta D: 15,16
ST   Penta E: 8,10
ST   TH01: 6,9
ST   TPOX: 10
ST   vWA: 17,18
DI   NCIt; C7712; Uveal melanoma
DI   ORDO; Orphanet_39044; Uveal melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C305 ! OMM2.2
OI   CVCL_C306 ! OMM2.3
OI   CVCL_C307 ! OMM2.5
OI   CVCL_C308 ! OMM2.6
SX   Male
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 22
//
RX   PubMed=9247253; DOI=10.1023/A:1018479011340;
RA   Chen P.W., Murray T.G., Uno T., Salgaller M.L., Reddy R.,
RA   Ksander B.R.;
RT   "Expression of MAGE genes in ocular melanoma during progression from
RT   primary to metastatic disease.";
RL   Clin. Exp. Metastasis 15:509-518(1997).
//
RX   PubMed=16772116; DOI=10.1016/j.cancergencyto.2005.11.016;
RA   White J.S., Becker R.L., McLean I.W., Director-Myska A.E., Nath J.;
RT   "Molecular cytogenetic evaluation of 10 uveal melanoma cell lines.";
RL   Cancer Genet. Cytogenet. 168:11-21(2006).
//
RX   PubMed=22236444; DOI=10.1111/j.1755-148X.2012.00971.x;
RA   Griewank K.G., Yu X.-X., Khalili J.S., Sozen M.M., Stempke-Hale K.,
RA   Bernatchez C., Wardell S., Bastian B.C., Woodman S.E.;
RT   "Genetic and molecular characterization of uveal melanoma cell
RT   lines.";
RL   Pigment Cell Melanoma Res. 25:182-187(2012).
//
RX   PubMed=22383533; DOI=10.1158/1535-7163.MCT-11-0676;
RA   Dutton-Regester K., Irwin D., Hunt P., Aoude L.G., Tembe V.,
RA   Pupo G.M., Lanagan C., Carter C.D., O'Connor L., O'Rourke M.,
RA   Scolyer R.A., Mann G.J., Schmidt C.W., Herington A., Hayward N.K.;
RT   "A high-throughput panel for identifying clinically relevant mutation
RT   profiles in melanoma.";
RL   Mol. Cancer Ther. 11:888-897(2012).
//
RX   PubMed=23849826; DOI=10.1016/j.ejca.2013.06.011;
RA   Amaro A., Mirisola V., Angelini G., Musso A., Tosetti F.I.,
RA   Esposito A.I., Perri P., Lanza F.B., Nasciuti F., Mosci C., Puzone R.,
RA   Salvi S., Truini M., Poggi A., Pfeffer U.;
RT   "Evidence of epidermal growth factor receptor expression in uveal
RT   melanoma: inhibition of epidermal growth factor-mediated signalling
RT   by gefitinib and cetuximab triggered antibody-dependent cellular
RT   cytotoxicity.";
RL   Eur. J. Cancer 49:3353-3365(2013).
//
RX   PubMed=28018010;
RA   Jager M.J., Bermudez Magner J.A., Ksander B.R., Dubovy S.R.;
RT   "Uveal melanoma cell lines: where do they come from? (an American
RT   Ophthalmological Society thesis).";
RL   Trans. Am. Ophthalmol. Soc. 114:T5-T5(2016).
//